Medicines In India

Cipla gets approval to market Afrezza insulin inhalation powder in India

Drug maker Cipla on Wednesday said it has received approval from the Central Drugs Standard Control Organisation for the distribution and marketing of Afrezza inhalation powder in India. Afrezza, a product created and manufactured by MannKind Corporation (MannKind) USA, is used to improve glycemic control in adult patients with diabetes mellitus. By bringing a game-changing, patient-centred solution to diabetes management in India, Cipla will make this drug accessible to all and empower millions to take control of their health with greater ease, the Mumbai-based company said in a statement. Afrezza is a rapid-acting insulin delivered through an inhaler compared to current insulins which are given as injections. Taken at the beginning of a meal, the medication dissolves rapidly upon oral inhalation into the lungs and delivers insulin quickly to the bloodstream. Afrezza starts working as early as 12 minutes and helps in reducing the rapid increase seen in sugar levels with meals. T

Johann Hari's book explores the risks of weight-loss drugs like Ozempic

Ozempic makes people eat less, but its impact on physical and psychological well-being is not well understood. Johann Hari's book explains the science behind it in an accessible way

'Allopathy medicines are poison': Ramdev stirs row days after SC reprimand

Ramdev's fresh statement followed two days after the Supreme Court closed contempt proceedings against Patanjali Ayurved co-founders for misleading the public through ill-informed advertisements

Govt plans regulatory crackdown on similar-sounding, look-alike drug brands

Drug manufacturers in India will soon be required to upload their product formulations and brand names on the government's portal

CDSCO says 52 medicines, including Paracetamol, failed quality check in May

The widespread nature of the issue stretches across different regions of the country, including Himachal Pradesh, Hyderabad, Waghodia, Vadodara, Andhra Pradesh, and Indore

Govt planning regulatory crackdown on look-alike, sound-alike drug names

In order to safeguard patients, the Drug Technical Advisory Board (DTAB) proposed banning the production and marketing of distinct drugs under identical brand names

Doctors not mandated to inform patients on drug side effects: Delhi HC

Delhi High Court dismissed a public interest litigation that sought to enforce the compulsory disclosure of drug side effects by doctors to the patients

World Homeopathy Day 2024: All about Homoeopathy and its benefits

The target of homoeopathy is to address and to give therapy the whole of an individual, including their character, way of life, hereditary predispositions, and disease history

Pharma firms bank on 'mother brands' to bolster new products: Report

A search conducted by Pharmarack showed that brands of any company, labelled under their mother brands, were observed to enjoy greater market share among their peers

Pharma regulation: A complex problem

Medicines are critical for human wellbeing but its regulation, which is inherently complex, is even more challenging in India

Assam tables bill aimed at eradicating non-scientific healing practices

The Assam Healing (Prevention of Evil) Practices Bill, 2024 has been framed to stop the propagation of the evil practices of magical healing in the name of treatment, the Bill says

Govt bans anti-cold fixed drug combination for under-four children

The Central Drugs Standard Control Organisation (CDSCO) has prohibited the use of anti-cold fixed drug combination in children below four years of age. Drugs Controller General of India (DCGI) Rajeev Raghuvanshi has asked the drug regulators of all states and Union territories to instruct the manufacturers of fixed drug combination (FDC) of Chlorpheniramine Maleate IP 2mg + Phenylephrine HCL IP 5mg drop/ml to insert warning that "FDC should not be used in children below 4 years of age" on label and package insert/promotional literature of the drug. In the letter, the DCGI stated that the FDC was declared as rational by the Professor Kokate Committee and based on its recommendation, this office had issued NOC for continued manufacturing and marketing of the FDC on July 17, 2015 under the 18-month policy decision. "Subsequently concerns have been raised regarding promotion of unapproved anti-cold drug formulation for infants," he said. The matter was deliberated in the Subject Expert

Abbott India recalls batches of Antacid Digene gel

In its letter, the DCGI warned that Digene may be unsafe and its use may result in adverse reaction

As G20 leader how India is ensuring quality of traditional medicine systems

Popular acceptance of Ayush is due to increased awareness and scientific validation, writes Sarbananda Sonowal

Aurobindo Pharma to launch HIV drug for children in 123 countries

The pharmaceutical company will launch its HIV triple combination product for children living with HIV in low- and middle-income countries under voluntary licence from ViiV Healthcare

What are generic medicines and how India became the 'pharmacy of the world'

India is the world's largest producer and exporter of generic drugs. But how did it manage to do so? Let us find out here

India vigilant, will never compromise on quality of medicines: Mandaviya

Mansukh Mandaviya said that there is 'zero tolerance' for spurious medicines and that 71 companies have been served with show-cause notices

NPPA to cap medicine prices to boost affordability, curb profiteering

The change could have financial implications for leading drug manufacturers like Abbott Laboratories, Bayer AG, and GlaxoSmithKline, among others

World Homeopathy Day 2023: History, Importance, Theme of this year

Homoeopathy is a 200-year-old and another form of medicine that claims to boost the body's ability to heal itself and stimulate a healing response

Issued show cause notice to 31 firms for online sale of drugs: Govt in LS

The CDSCO has issued show cause notices to 31 firms based on representations raising concerns over the sale of drugs online or through other electronic platforms in contravention to the provisions of the Drugs and Cosmetics Act, 1940, the government informed the Lok Sabha on Friday. Cases concerning the quality of drugs, when reported, was is taken up with the State Licensing Authority (SLA) concerned for necessary action under the provisions of the Drugs and Cosmetics Act, Minister of State for Health Bharati Pravin Pawar said in a written reply. The SLAs are empowered to take action on violation of any conditions of such licenses, including prosecution in an appropriate court of law. She also told the Lower House of Parliament that as informed by Central Drugs Standard Control Organisation (CDSCO), various representations are received raising concerns regarding the sale of drugs through online or other electronic platforms in contravention to the provisions of the Drugs and ...